Molecular Imaging of Infections: Advancing the Search for the Hidden Enemy

Molecular Imaging of Infections: Advancing the Search for the Hidden Enemy

Abstract Even before the coronavirus disease 2019 pandemic, infections were a major threat to human health, as the third leading cause of death and the leading cause of morbidity among all human diseases. Although conventional imaging studies are routinely used for patients with infections, they pro...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases Vol. 228; no. Supplement_4; pp. S233 - S236
Main Authors: Hammoud, Dima A, Clifford Lane, H, Jain, Sanjay K
Format: Journal Article
Language:English
Published: United States Oxford University Press 03-10-2023
Subjects:
Coronaviruses
COVID-19
Humans
Infections
Medical imaging
Medical laboratories
Medical technology
Molecular biology
Molecular Imaging
Morbidity
Supplement
pathogen-specific
MRI
nuclear medicine
PET
SPECT
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Even before the coronavirus disease 2019 pandemic, infections were a major threat to human health, as the third leading cause of death and the leading cause of morbidity among all human diseases. Although conventional imaging studies are routinely used for patients with infections, they provide structural or anatomic information only. Molecular imaging technologies enable noninvasive visualization of molecular processes at the cellular level within intact living subjects, including patients, and hold great potential for infections. We hope that this supplement will spur interest in the field and establish new collaborations to develop and translate novel molecular imaging approaches to the clinic.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Potential conflicts of interest. DAH is first named inventor for pending patent application US2020/044446 on radiolabeled sugars for imaging of fungal infections, filed by the NIH. SKJ is an inventor for patent US20150250906A1 on bacteria-specific labeled substrates as imaging biomarkers, filed by Johns Hopkins University; SKJ is an inventor for pending patent USPA #63/071,755 on the solid-phase cartridge to formulate ready-to-use 18F-FDS, filed by Johns Hopkins University. SKJ has research grants from Novobiotic LLC, USA, T3 Pharma, Switzerland, and Fujirebio Diagnostics, Inc., USA and is a scientific consultant for Novobiotic LLC, USA. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
ISSN:0022-1899
1537-6613
1537-6613
DOI:10.1093/infdis/jiad079